Sugi Predict

Sugi Predict / Compounds / SCHEMBL4367748

SCHEMBL4367748

SCHEMBL4367748

COc1cc2nccc(Oc3ccc4nc(NC(=O)c5ccc(F)cc5)sc4c3)c2cc1OC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCD O00767 6/20 0.68
▸ MEN1 O00255 2/20 0.68
▸ NPC1 O15118 2/20 0.68
▸ RAB9A P51151 2/20 0.68
▸ KMT2A Q03164 2/20 0.68
▸ MET P08581 3/20 0.67
▸ KDR P35968 10/20 0.59
▸ PDGFRA P16234 5/20 0.59
▸ AXL P30530 3/20 0.56
▸ KIT P10721 2/20 0.56
▸ FGFR2 P21802 1/20 0.56
▸ AURKA O14965 1/20 0.54
▸ RIPK2 O43353 1/20 0.54
▸ ABCB11 O95342 1/20 0.54
▸ ABL1 P00519 1/20 0.54
▸ EGFR P00533 1/20 0.54
▸ ERBB2 P04626 1/20 0.54
▸ NTRK1 P04629 1/20 0.54
▸ LCK P06239 1/20 0.54
▸ PGR P06401 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4379209 0.94 MET (0.70) SCDMEN1NPC1RAB9AKMT2A
SCHEMBL4378894 0.92 MET (0.68) SCDMEN1NPC1RAB9AKMT2A
SCHEMBL4379965 0.91 MET (0.65) SCDMEN1NPC1RAB9AKMT2A
SCHEMBL4372566 0.91 MET (0.67) SCDMEN1NPC1RAB9AKMT2A
SCHEMBL4368604 0.91 MET (0.77) SCDMEN1NPC1RAB9AKMT2A
SCHEMBL4379203 0.91 MET (0.66) SCDMEN1NPC1RAB9AKMT2A
SCHEMBL4373589 0.90 MET (0.66) SCDMEN1NPC1RAB9AKMT2A
SCHEMBL4370551 0.87 MET (0.64) SCDMEN1NPC1RAB9AKMT2A
SCHEMBL4379986 0.87 SCD (0.71) SCDMEN1NPC1RAB9AKMT2A
SCHEMBL13587170 0.87 AXL (0.71) SCDMEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 — — US disclosed
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 — — US disclosed
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 — — US disclosed
US-20050245547-A1 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma AMGEN INC. 2005-11-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245547-A1 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma HGF, MET, HGFAC SCD 3456/4885MEN1 1636/4885NPC1 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.